Bristol-Myers Squibb Co (BMY) Holdings Decreased by Macquarie Group Ltd.

Macquarie Group Ltd. decreased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 11.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 240,534 shares of the biopharmaceutical company’s stock after selling 31,748 shares during the quarter. Macquarie Group Ltd.’s holdings in Bristol-Myers Squibb were worth $15,332,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 15 shares during the period. Chilton Investment Co. LLC boosted its stake in shares of Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the period. Keel Point LLC boosted its stake in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 39 shares during the period. Finally, Hudock Capital Group LLC boosted its stake in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 49 shares during the period. 69.74% of the stock is currently owned by hedge funds and other institutional investors.

BMY has been the subject of several research analyst reports. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Jefferies Group reiterated a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 target price for the company in a research note on Wednesday, September 27th. UBS Group reiterated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Finally, SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $65.11.

Shares of Bristol-Myers Squibb Co (BMY) opened at $61.83 on Friday. The stock has a market capitalization of $101,229.90, a price-to-earnings ratio of 24.34, a P/E/G ratio of 2.18 and a beta of 1.18. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 earnings per share. equities analysts predict that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.59%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 62.99%.

In related news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Co (BMY) Holdings Decreased by Macquarie Group Ltd.” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://transcriptdaily.com/2018/01/19/bristol-myers-squibb-co-bmy-holdings-decreased-by-macquarie-group-ltd.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply